Progenics Pharmaceuticals Acquires Molecular Insight Pharmaceuticals

Progenics Pharmaceuticals has acquired Molecular Insight Pharmaceuticals, a clinical-stage specialty pharmaceutical company focused on critical unmet diagnostic and therapeutic needs of the prostate cancer patient. O’Melveny & Myers represented Progenics Pharmaceuticals.

DealsNorth AmericaUSBriefs